Compliance with the European Falsified Medicines Directive (FMD) goes beyond adding a unique code to each drug product. It is a complex process that involves IT system creation, regulatory data uploading, new packaging requirements, supply chain adaptation and far more.
In the article, Erik discusses how attitudes to serialisation have changed, the lessons learned so far and the challenges faced by companies throughout the supply chain. He describes the shift to serialisation as a positive step in the supply chain that has been needed for some time. During the roundtable the experts also deliberate over who is responsible for ensuring products are serialised and some of the short and long-term effects and benefits of serialisation on the industry.
Read the full discussion and Erik’s comments from a CDMO perspective here.